6d ago
FOSUN PHARMA - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ## Announcement of Resolutions of the 38th Meeting (Extraordinary Meeting) of the 10th Board of Directors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 02196)
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
Hereby set forth the "Announcement on Resolutions of the 38th Meeting of the 10th Board of Directors (Extraordinary Meeting)" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange for reference only.
By order of the board of directors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Chairman
Chen Yuqing
China, Shanghai
August 28, 2026
As of the date of this announcement, the company’s executive directors are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the company’s non-executive directors are Mr. Chen Qiyu and Mr. Pan Donghui; the company’s independent non-executive directors are Mr. Yu Zishan, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the company’s employee director is Ms. Yan Jia.
*For identification only
Securities Code: 600196 Securities Abbreviation: Fosun Pharma Announcement Number: Lin 2026-114
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Announcement of Resolutions of the 38th Meeting of the 10th Board of Directors (Extraordinary Meeting)
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
The 38th meeting (extraordinary meeting) of the 10th board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company") was held on August 28, 2026. All directors attended the meeting via communication. The convening of this meeting complied with the provisions of the Company Law of the People's Republic of China, other relevant laws and regulations, and the Articles of Association of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. The meeting reviewed and reached the following resolutions:
- Consider and approve the proposal on the reserved grant of the 2025 A-share stock option incentive plan.
According to the "Shanghai Fosun Pharma (Group) Co., Ltd. 2025 A-Share Stock Option Incentive Plan" and related authorizations that have been reviewed and approved by the company's first extraordinary shareholders' meeting in 2025 (hereinafter referred to as the "Shareholders' Meeting"), the board of directors believes that all reserved grant conditions stipulated in the plan have been achieved, and agrees to use August 28, 2026 as the reserved grant date to grant a total of 725,100 shares to a total of 100 reserved grant incentive targets. A-share options and handle related matters required for the grant.
According to the provisions of the plan, when the board of directors voted on this proposal, the company's directors, Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin, Mr. Liu Yi and Ms. Yan Jia, who were the first recipients of incentives, abstained from voting, and the remaining 6 directors (including 4 independent non-executive directors) participated in the voting.
Voting results: 6 votes in favor, 0 votes against, and 0 abstentions.
This proposal has been reviewed and approved by the Remuneration and Appraisal Committee of the Board of Directors before being considered by the Board of Directors.
For details, please refer to the "Announcement on the Reserved Grant of the 2025 A-Share Stock Option Incentive Plan" released on the same day (Announcement No.: Pro 2026-115).
- Consider and approve the proposal on the reserved grant of H-share restricted stock units plan in 2025.
According to the "Shanghai Fosun Pharma (Group) Co., Ltd. 2025 H-Share Restricted Share Unit Plan" and related authorizations that have been reviewed and approved by the company's shareholders' meeting, the board of directors believes that all reserved grant conditions stipulated in the plan have been achieved, and agrees to use August 28, 2026 as the reserved grant date to grant a total of 1,695,400 H-share restricted share units to a total of 100 qualified employees, and handle the relevant matters required for the grant.
According to the provisions of the plan, when the board of directors voted on this proposal, the company's directors, Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin, Mr. Liu Yi and Ms. Yan Jia, who were the first recipients of the grant, abstained from voting, and the remaining 6 directors (including 4 independent non-executive directors) participated in the voting.
Voting results: 6 votes in favor, 0 votes against, and 0 abstentions.
This proposal has been reviewed and approved by the Remuneration and Appraisal Committee of the Board of Directors before being considered by the Board of Directors.
For details, please refer to the "Announcement on the Reserved Grant of H-Share Restricted Share Unit Plan in 2025" released on the same day (Announcement No.: Pro 2026-116).
Announcement is hereby made.
Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
August 28, 2026